**Original Article**

**Demodex blepharokeratoconjunctivitis affecting young patients: A case series**

*Nikunj Vinodbhai Patel, Umang Mathur, Arpan Gandhi*, Manisha Singh

**Purpose:** To report clinical characteristics of *Demodex* blepharokeratoconjunctivitis affecting young corneal involvement. The pathogenesis of this disorder is largely unclear, with few studies suggesting colonization of lid margins with bacteria such as *Staphylococcus aureus* and *Propionibacterium acnes* as the causative factors for BKC.[1,2] Young patients with chronic red eye and corneal vascularization are often diagnosed as atopic or allergic disease or even herpetic disease and are chronically treated with steroids and develop unavoidable grave complications of the treatment.

Historically, literature has been reported on *Demodex* over 176 years ago with ophthalmic literature dating back to 1967.[3] Ophthalmologically, *Demodex* species have been implicated in some pathologies, most common being blepharitis.[4] Other associations include madarosis, trichiasis, chalazia, pterygium, floppy eyelids, and basal cell carcinoma.[5-8] However, corneal manifestation of *Demodex* infestation in young patients has been reported recently, highlighting the importance of *Demodex* as a causative agent for chronic inflammation of the ocular surface, including corneal involvement.[9,10]

We present a case series of 26 eyes of 14 patients wherein we were able to identify the cause of the pathology and describe clinical characteristics.

**Methods**

We conducted a single-center observational study from April 2017 to December 2018. Patients with a diagnosis of demodicosis based on eyelash sampling and with corneal manifestations were included in the study. Sociodemographic data including age, sex, economic status, and general hygiene were noted. Medical history was noted for any previous treatment taken, duration of previous treatment, response to previous treatment, and current complaints. Complete ocular examination was done including best corrected visual acuity, anterior segment examination noting the presence of blepharitis with or without cylindrical dandruff (CD), the presence of conjunctival inflammation, corneal signs with quadrant of corneal vascularization, laterality, opacities, thinning and infiltrate; lens status, presence of glaucoma, and retinal pathology were also noted.

Once clinical suspicion of demodicosis was made, eyelash sampling was done after taking informed consent forms from the patients. Eyelashes with CDs were preferred.[11] In the absence of CDs, those eyelashes were chosen which had fine cream-colored bristles protruding from the undersurface of the opening of the eyelash follicle.[12] At least two nonadjacent eyelashes were taken from each of the lids. We used the method described by Mastrota et al. of rotating the eye lash before epilating for better yield of mites.[13] Eyelashes were placed on two different slides, right and left and were evaluated under light microscope. Fluorescein strip moistened with 0.9% normal saline was placed at the edge of the cover slip to dissolve the debris around the mites.[14] After a waiting period of 5 min, a

Blepharokeratoconjunctivitis (BKC) is a chronic inflammatory disease of the lid margin with secondary conjunctival and corneal involvement. The pathogenesis of this disorder is largely unclear, with few studies suggesting colonization of lid margins with bacteria such as *Staphylococcus aureus* and *Propionibacterium acnes* as the causative factors for BKC.[1,2] Young patients with chronic red eye and corneal vascularization are often diagnosed as atopic or allergic disease or even herpetic disease and are chronically treated with steroids and develop unavoidable grave complications of the treatment.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

**Cite this article as:** Patel NV, Mathur U, Gandhi A, Singh M. *Demodex* blepharokeratoconjunctivitis affecting young patients: A case series. Indian J Ophthalmol 2020;68:745-9.
single examiner examined the slides under 20X magnification for identification of mites. The presence of Demodex mites on any eyelash was considered positive. External photography of the lid margins and the cornea was done.

Once diagnosed with demodicosis, patients were treated with equal concentration of tea tree oil and olive oil lid scrubs and two doses of oral ivermectin (200 μg/kg, 1 week apart).[13] Fluorometholone (0.1%) eye drops were prescribed in tapering dosage for 3 weeks along with the topical lubricants. Patients were explained the method of using tea tree oil twice daily for 3 months and were asked to follow-up at 3 weeks, 6 weeks, and 3 months. Thereafter, patients were asked to continue lid scrubbing with tea tree oil on weekly basis depending on the response and chronicity.

On follow-up, patients were evaluated for symptomatic relief and decrease in ocular surface inflammation in terms of congestion and corneal vascularization.

The study was approved by the institutional review board and adhered to the tenets of the Declaration of Helsinki.

**Results**

During the study period of April 2017 to December 2018, 49 patients were positive for Demodex mites in eyelash sampling. 26 eyes of 14 patients had corneal findings and were included in the study [Table 1]. Median age was 27 years (range: 11–39 years) and included 11 males and 3 females. The median age from the beginning of symptoms was 17.5 years (range: 8–30.6 years). Only one of the 14 patient availed nonpaying services of the hospital, while the rest belonged to a high socioeconomic status with good personal hygiene.

All the patients included in the study had a chronic history of relentless, refractory red eyes with median duration of symptoms being 5 years (range: 2 months to 20 years) [Fig. 1]. Six patients had history of more than 10 years and only two patients had history less than 6 months. Only 2 patients had unilateral findings, rest all had bilateral.

Most common symptom was redness (n = 14), present in all of the fourteen patients, followed by ocular irritation (n = 8), diminution of vision (n = 7), photophobia (n = 4), itching (n = 3), pain (n = 2), and drooping of eyes (n = 1). Best corrected visual acuity was less than 20/60 in four eyes. Before the diagnosis of demodicosis was made, all the patients had multiple misdiagnosis such as vernal keratoconjunctivitis (VKC) (n = 7), viral keratitis (n = 5), phlyctenular KC (n = 3) [Fig. 2], limbal stem cell deficiency (LSCD) (n = 1), superior limbic keratitis (n = 1), episcleritis (n = 1), Terrien’s degeneration (n = 1), dry eye (n = 1), acanthamoeba keratitis (n = 1), bacterial keratitis (n = 2), and microsporidiosis (n = 1). Three patients had facial rosacea. As they were misdiagnosed earlier, they had received various other treatments such as topical and oral steroids, oral azathioprine, topical ciclosporin, topical tacrolimus, antivirals,

**Table 1: Clinical information of patients with Demodex blepharokeratoconjunctivitis**

| Case no | Age (years) | Sex | Symptoms | Duration of symptoms | Rosacea | Corrected visual acuity (VA) | Cylindrical dandruff | Corneal findings | Right eye | Left eye |
|---------|-------------|-----|----------|---------------------|---------|----------------------------|---------------------|-----------------|-----------|----------|
| 1       | 31          | M   | redness, pain | 6 months           | No      | 20/20                      | Yes (diffuse)       | inferior vaso | inferior      | minimal inferior vaso |
| 2       | 14          | F   | redness, itching | 5 years           | No      | 20/20                      | Yes (diffuse)       | inferior      | inferior vascularization + scar | inferior vascularization |
| 3       | 23          | M   | redness, ocular irritation, DOV, photophobia | 10 years | No | 20/60 20/80 | No | 360 vascularization with corneal scars | 360 vascularization with corneal scars |
| 4       | 24          | M   | redness, ocular irritation, DOV | 12 years | Yes | 20/20 20/20 | No | superior vascularization | superior vascularization + scar |
| 5       | 11          | M   | redness, itching | 3 years           | No      | 20/20                      | Yes (sporadic)      | superior      | superior vascularization, infiltrate | normal |
| 6       | 29          | M   | redness, itching, dropping of eyelids | 12 years | No | 20/20 20/20 | No | superior vascularization | superior vascularization, infiltrate |
| 7       | 30          | M   | redness, pain, DOV | 2 years           | No      | 20/80 20/20 | No | PUK | inferior vascularization |
| 8       | 23          | F   | redness, ocular irritation, DOV, photophobia | 5 years | No | 20/20 20/20 | Yes (sporadic) | superior vascularization | superior vascularization |
| 9       | 25          | F   | redness, ocular irritation, DOV | 10 years | No | 20/40 20/30 | Yes (sporadic) | 360 vascularization | 360 vascularization |
| 10      | 35          | M   | redness, ocular irritation, photophobia | 20 years | No | 20/30 20/20 | No | corneal scar | corneal scar |
| 11      | 31          | M   | redness, DOV | 1 year            | No      | 20/30 20/400 | No | corneal scar | inferior vascularization, infiltrates |
| 12      | 28          | M   | redness, ocular irritation, DOV, photophobia | 3 years | Yes | 20/120 20/20 | Yes (sporadic) | superior vascularization, infiltrate, scar | corneal scar |
| 13      | 39          | M   | redness, ocular irritation | 12 years | No | 20/20 20/20 | No | superior vascularization, scar | inferior vascularization, scar |
| 14      | 23          | M   | redness | 1 year           | Yes | 20/20 20/20 | No | superior vascularization, scar | inferior vascularization |

DOV: Diminution of vision
All patients had received chronic steroid therapy, with four patients manifesting steroid induced side effects with advanced glaucoma (n = 2) and cataract (n = 2, one operated). Three patients were using scleral contact lenses, one of whom had developed giant papillary conjunctivitis due to chronic use. None of the other patients had papillae in upper tarsal conjunctiva excluding the diagnosis of allergic conjunctivitis.

CDs were present in 6 patients at the time of diagnosis. Eight eyes had inferior vascularization, seven eyes had superior vascularization, and five eyes had vascularization in all quadrants. Twelve eyes had corneal scars; three had marginal infiltrates; phlycten and peripheral ulcerative keratitis (PUK) in one eye each.

We treated all these patients with tea tree oil and oral ivermectin. At the end of 3 months all patients showed clinical improvement in signs and symptoms. Thirteen patients were off topical steroids after 3 weeks of initial treatment. One patient had recurrence on tea tree oil therapy and needed topical steroids in low dosage during the study period. Patient with PUK had resolved within 3 weeks with residual scarring.

Figure 1: Photographs with different corneal findings. Presence of either inferior, superior or all-around corneal vascularisation (a-l); active infiltrates (a, b, j, k) or scars (c, d, h, i, l); phlycten (b) and peripheral ulcerative keratitis (g)

Figure 2: Patient misdiagnosed as a case of phlyctenular conjunctivitis. Patient had phlycten-like nodule at 9 o’clock (arrow in a) and florid inferior vascularization (a) with diffuse cylindrical dandruff (b). Treatment with tea tree oil lid scrubs and oral ivermectin resulted in resolution of phlycten (arrow in c) and regression of vascularization. Eyelashes also showed improvement (d)

antibiotics, antifungals, antiamebicidal, and oral antitubercular therapy. All patients had received chronic steroid therapy, with four patients manifesting steroid induced side effects with advanced glaucoma (n = 2) and cataract (n = 2, one operated). Three patients were using scleral contact lenses, one of whom had developed giant papillary conjunctivitis due to chronic use. None of the other patients had papillae in upper tarsal conjunctiva excluding the diagnosis of allergic conjunctivitis.

CDs were present in 6 patients at the time of diagnosis. Eight eyes had inferior vascularization, seven eyes had superior vascularization, and five eyes had vascularization in all quadrants. Twelve eyes had corneal scars; three had marginal infiltrates; phlycten and peripheral ulcerative keratitis (PUK) in one eye each.

We treated all these patients with tea tree oil and oral ivermectin. At the end of 3 months all patients showed clinical improvement in signs and symptoms. Thirteen patients were off topical steroids after 3 weeks of initial treatment. One patient had recurrence on tea tree oil therapy and needed topical steroids in low dosage during the study period. Patient with PUK had resolved within 3 weeks with residual scarring.

Representative case

Case 3

A 13-year-old boy presented to us 8 years back with history of redness, itching and diminution of vision in both eyes of 2 years duration. He was diagnosed with allergic KC elsewhere and was treated with topical steroids and ciclosporin eye drops. He continued to have several episodes of redness with marginal
keratitis and increasing corneal vascularization. In 2012, we thought it was viral keratitis and treated him for the same for some time, but he did not show improvement. Subsequently, he had an episode of phlyctenular conjunctivitis and was investigated for tuberculosis, an association of which is not uncommon in Indian context. However, he did not show evidence of tuberculosis and he continued to have episodes of ocular surface inflammation that were managed by topical steroids. He was prescribed scleral contact lenses to improve his vision. In 2015, he developed steroid-induced glaucoma and was managed on antiglaucoma medication. After 10 years of the disease, he was suspected to have demodicosis and eyelash sampling confirmed the disease. Six months of therapy with tea tree oil has made him symptom-free with no evidence of recurrence [Fig. 3].

All of our cases were young, suffering from chronic BKC and had undergone multiple consultations. These cases were diagnostic dilemmas and were treated for long time with topical steroids. It did not occur to us to sample the eyelashes earlier even though half of them had CD on eyelashes. When eyelash sampling was done it came out to be positive for Demodex mites. Recurrence rates reduced after treatment with tea tree oil and patients were symptomatically better.

**Discussion**

Our case series demonstrate the presence of Demodex mite in eyelashes as a cause of BKC in young and healthy patients, even with good general hygiene. The disease was chronic in nature, causing severe vision impairment in many patients due to corneal scarring and vascularization or complication of steroid usage. In most cases, it took several years before the diagnosis of demodicosis could be confirmed.

While it is well-established that prevalence of Demodex in eyelashes increases with age, our series had corneal manifestation of demodicosis in young individuals. Liang et al. have also described keratitis in the presence of Demodex infestation in pediatric and young patients. It is known that greatest concentration of Demodex mite is found where sebaceous glands are numerous. As demodices are voracious maters, males travel from one hair follicle to other in search of female mites. Thus, the concentration of mites would be greater where the density of follicles is higher such as facial areas. During adolescence, sebum production increases under the influence of sex hormones, especially in the facial area, including eye lashes. Thus, it is possible that mites migrate from facial area to eye lashes in search of a conducive environment, causing manifestation of BKC in young individuals. Mites may incite hypersensitivity reaction in younger people and as age advances, immunity fades and the mites just colonize and survive in harmony.

Presence of CDs increases the yield of Demodex. In the study conducted by Kheirkhah et al., equal number of patients had diffuse and sporadic CDs. Whereas all the pediatric patients with blepharocconjunctivitis in Liang et al.’s study had sporadic CDs. In our case series, CDs were absent in eight patients and diffuse in only two patients. Earlier studies and the present study make a suggestion that CDs may or may not be present in patients with corneal manifestation.

It is believed that Demodex proliferate in eyelashes as eyes being surrounded by protruding structures such as eyebrows, nose, and cheeks are not accessible to cleaning during daily hygiene. Lee et al. have suggested association between hygiene and Demodex counts while determining relationship between Demodex infestation and ocular discomfort. Otherwise, studies have not been conducted with respect to hygiene and Demodex infestations of eyelashes. As noted earlier, CDs were absent in more than half of our patients suggesting that hygiene may only be one of the contributing factor in colonization and pathogenicity of Demodex BKC.

Most patients had several years of empirical treatment before the etiology of demodicosis could be confirmed. Like in previous studies, viral keratitis and allergic conjunctivitis were the most common misdiagnosis. Our series emphasizes the importance of early diagnosis to reduce vision loss due to corneal scarring and steroid-induced complications. All patients in our series had vascularization while only two pediatric patients reported by Liang et al. had corneal vascularization. Vascularization of the cornea increases with the chronicity of the disease. Superior and inferior distribution of vascularization can be explained by the fact that the chemical mediators secreted by Demodex spread over the cornea as the eyelids rub them during blinking and causes inflammation in either the superior or inferior part of the cornea.

Tea tree oil is widely used in cosmetics and for various skin ailments including acne and rosacea. Tea tree oil has been shown to reduce Demodex infestation and ocular symptoms related to it. Terpinen-4-ol is the most active ingredient responsible for the anti-inflammatory effects. Previous studies and our results strongly suggest that the use of tea tree oil minimizes the need of long-term steroids and can prevent serious complications associated with it.

**Figure 3:** Representative case 3. Right eye (a) showing diffuse conjunctival inflammation and corneal scars. With 10 years history of multiple misdiagnosis and treatments, eyelashes were clean (b), without any cylindrical dandruff. Tea tree oil therapy resulted in significant reduction in conjunctival inflammation (c)
Our study and existing literature suggest that *Demodex BKC* is a clinical spectrum primarily involving lid margins and has varied manifestations across different age groups. *Demodex* probably starts colonizing eyelashes early in life inciting humoral immunity and causing ocular surface inflammation. Early diagnosis is a challenge as clinical presentation is often confusing. *Demodex* as cause of ocular surface inflammation should always be kept in mind in patients with marginal keratitis, peripheral scarring, and vascularization involving superior or inferior quadrants with or without CDs.

Our study had few limitations. We did not differentiate between *Demodex folliculorum* and *Demodex brevis* which could have helped us in better understanding of the disease. *D. brevis* is difficult to isolate with the standard epilation technique as they are very few in number and buried deep within the sebaceous glands. *Demodex* count per eyelash was not taken into consideration as with clinical experience we realized that epilation does not yield all the mites. Better diagnostic techniques are required to help in associating the link between *Demodex* mite and corneal disease. Our series does not include patients of BKC where demodicosis was suspected but eyelash sampling was negative for the mite. Age- and sex-matched population-based studies are also required to know the incidence of *Demodex* in asymptomatic population and to prove its association in those affected.

In his paper, Coston states “often several ophthalmologists have been consulted who have said: ‘I find nothing to explain your symptoms’. Many patients have been tranquilized, ‘dropped’, ‘steroided’, and called neurotic, because the ophthalmologist did not think of *Demodex* or know how to find and treat them.” The paper was published in 1967, and we believe that the statements made at that time still hold true and ophthalmologists should search for *Demodex* as a cause for chronic red eye and keratitis.

**Conclusion**

*Demodex* infestation of eyelids causes chronic blepharokeratoconjunctivitis in healthy children and young adults. It is often missed or is misdiagnosed as viral keratitis or allergic conjunctivitis. Demodicosis can be confirmed by simple epilation and microscopy. Early diagnosis and appropriate treatment is gratifying.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understand that name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Gupta N, Dhawan A, Beri S, D’Souza P. Clinical spectrum of pediatric blepharokeratoconjunctivitis. J AAPOS 2010;14:527–9.
2. Teo L, Mehta JS, Htoon HM, Tan DT. Severity of pediatric blepharokeratoconjunctivitis in Asian eyes. Am J Ophthalmol 2012;153:564-70.
3. Coston TO. *Demodex folliculorum* blepharitis. Trans Am Ophthalmol Soc 1967;65:361-92.
4. Zhao YE, Wu LP, Hu L, Xu JR. Association of blepharitis with *Demodex*: A meta-analysis. Ophthalmic Epidemiol 2012;19:95-102.
5. Liang L, Ding X, Tseng SC. High prevalence of *Demodex brevis* infestation in chalazia. Am J Ophthalmol 2014;157:342-8.
6. Huang Y, He H, Sheha H, Tseng SC. Ocular demodicosis as a risk factor of pterygium recurrence. Ophthalmology 2013;120:1341-7.
7. Van Nouhuys HM, van den Bosch WA, Lemij HG, Mooy CM. Floppy eyelid syndrome associated with *Demodex* Brevis. Orbit 1994;13:125-9.
8. Erbagci Z, Erbagci I, Ekerliç S. High incidence of demodicidosis in eyelid basal cell carcinomas. Int J Dermatol 2003;42:567-71.
9. Kheirkhah A, Casas V, Li W, Raja VK, Tseng SC. Corneal manifestations of *Demodex* infestation. Am J Ophthalmol 2007;143:743-9.
10. Luo X, Li J, Chen C, Tseng S, Liang L. Ocular demodicosis as a potential cause of ocular surface inflammation. Cornea 2017;36(Suppl 1):59-14.
11. Gao YY, Di Pascaule MA, Li W, Liu DTS, Baradaran-Rafii A, Elizondo A, et al. High prevalence of *Demodex* in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci 2005;46:3089-94.
12. Hom MM, Mastrota KM, Schachter SE. *Demodex*: Clinical cases and diagnostic protocol. Optom Vis Sci 2013;90:e198-205.
13. Mastrota KM. Method to identify *Demodex* in the eyelash follicle without epilation. Optom Vis Sci 2013;90:e172-4.
14. Kheirkhah A, Blanco G, Casas V, Tseng SC. Fluorescein dye improves microscopic evaluation and counting of *Demodex* in blepharitis with cylindrical dandruff. Cornea 2007;26:697-700.
15. Holzchuh FG, Hida RY, Moscovici BK, Albers MBV, Santo RM, Kara-Jose N, et al. Clinical treatment of ocular *Demodex folliculorum* by systemic ivermectin. Am J Ophthalmol 2011;151:1030-4.
16. Biernat MM, Rusiecka-Ziolkowska J, Piatkowska E, Helemejko I, Biernat P, Gościniak G. Occurrence of *Demodex* species in patients with blepharitis and in healthy individuals: A 10-year observational study. Jpn J Ophthalmol 2018;62:628-33.
17. Liang L, Safran S, Gao Y, Sheha H, Raja VK, Tseng SC. Ocular demodicosis as a potential cause of pediatric blepharokeratoconjunctivitis. Cornea 2010;29:1386-91.
18. Liang L, Liu Y, Ding X, Ke H, Chen C, Tseng SC. Significant correlation between meibomian gland dysfunction and keratitis in young patients with *Demodex brevis* infestation. Br J Ophthalmol 2018;102:1098-102.
19. Ruffi T, Mumcuoglu Y. The hair follicle mites *Demodex folliculorum* and *Demodex brevis*: Biology and medical importance. A review. Dermatologica 1981;162:1-11.
20. Schaller M, Plewig G. Structure and function of eccrine, apocrine, and sebaceous glands. In: Bolognia JL, Jorizza JL, Schaffer JV, editors. Dermatology. 3rd ed. Elsevier; 2012. p. 539-44.
21. Nicholls SG, Oakley CL, Tan A, Vote BJ. *Demodex* species in human ocular disease: New clinicopathological aspects. Int Ophthalmol 2017;37:303-12.
22. Lacey N, Russell-Hallinan A, Zouboulis CC, Powell FC. *Demodex* mites modulate sebocyte immune reaction: Possible role in the pathogenesis of rosacea. Br J Dermatol 2018;179:420-30.
23. Bevins CL, Liu FT. Rosacea: Skin innate immunity gone awry? Nat Med 2007;13:904-6.
24. Lacey N, Kavanagh K, Tseng SC. Under the lash: *Demodex* mites in human diseases. Biochem (Lond) 2009;3:2-6.
25. Lee SH, Chun YS, Kim JH, Kim ES, Kim JC. The relationship between *Demodex* and ocular discomfort. Invest Ophthalmol Vis Sci 2010;51:2906-11.
26. Gao YY, Di Pascaule MA, Elizondo A, Tseng SC. Clinical treatment of ocular demodicidosis by lid scrub with tea tree oil. Cornea 2007;26:136-43.
27. Tighe S, Gao YY, Tseng SC. Terpinen-4-ol is the most active ingredient of tea tree oil to kill *Demodex* mites. Trans Vis Sc Tech 2013;2:2.